Osteoarthritis and cartilage
-
Osteoarthr. Cartil. · Jan 2009
Randomized Controlled Trial Multicenter Study Comparative StudyA 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis.
To compare the safety and efficacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain associated with knee osteoarthritis (OA). ⋯ APAP ER 3900 mg daily was noninferior to rofecoxib 12.5mg daily, but noninferiority was not established to rofecoxib 25mg daily. APAP ER was well tolerated and no safety issues were identified. Based on the results of this study, APAP ER 3900 mg daily is an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs), such as rofecoxib, in treating pain associated with knee OA.